- The International Psycho-Oncology Society Introduce a New Global
Quality of Life Initiative With the Support of Roche
BASEL, Switzerland, Nov. 29 /CNW/ - Concerning results from a Europe-wide
survey released today during Lung Cancer Awareness Month reveal that one in
three lung cancer patients feel that they are not receiving the emotional
support they need to manage their life-threatening disease. Patients surveyed
say support is essential during their diagnosis and treatment, but many are
still not benefiting from the services available in hospitals and patient
groups because they do not address the particular burdens unique to a lung
cancer diagnosis(1). Lung cancer is the most common form of cancer and
Europe's most deadly, claiming almost 1,000 lives every day(2).
"Nothing prepared me for the wide range of emotions that accompanies a
lung cancer diagnosis," says lung cancer patient Ana Motta, Spain, who was
diagnosed in January 2007. "Programs that are developed with our feelings in
mind are sorely needed, especially those that we can use when we are at home."
To fill the void currently faced by lung cancer patients and their
caregivers, Roche and the International Psycho-Oncology Society (IPOS) have
introduced INSPIRE, an innovative global initiative to improve quality of life
for lung cancer patients worldwide. This unique program will provide patients
and caregivers with comprehensive practical and emotional guidance that is
customised to their needs. It will include:
- Coping and self-help techniques
- Advice to improve communication among patients, caregivers and health
- Relaxation methods to help patients take a more positive and active
role in their cancer care.
The INSPIRE resources will be available next year, in formats adapted to
suit each country, including, but not limited to, booklets, CD-ROMs and online
"Emotionally, lung cancer patients have a particularly difficult journey
because they are often diagnosed at a very advanced stage of their disease,"
says Dr. Luigi Grassi, President of IPOS and Professor and Chair of
Psychiatry, University of Ferrara, Italy. "It is, therefore, critical that we
have programs and support vehicles that are designed with the specific needs
in mind of lung cancer patients and their carers/families. IPOS is pleased to
be involved with Roche in this first-of-its-kind patient program."
Psycho-oncology is a growing discipline within the area of cancer care,
focusing on the psychological, behavioral and social impact of cancer on
patients and their caregivers. When the emotional distress of lung cancer is
neglected, the patient's health and quality of life often deteriorates.
Psycho-oncologists help patients and their caregivers to cope with their
disease and to manage their overwhelming emotions that often accompany a
cancer diagnosis and its treatment.
For more information on INSPIRE, please contact Lester B. Davis,
International Communication Manager, Tarceva at Lester.Davis@Roche.com or May
Baccari, Resolute Communications at May.Baccari@resolutecommunications.com.
For more information about IPOS and how you can support its critical
programmes, visit http://www.ipos-society.org.
About the survey
Over a period of two months, 252 lung cancer patients across the UK,
Germany, Italy, France and Spain were surveyed on their experiences with being
diagnosed with and treated for lung cancer. The survey was commissioned by
Roche and conducted by an independent research consultancy, Patient Research,
and was carried out using a combination of telephone and internet
methodologies. All survey respondents were offered full anonymity and were
qualified by the researchers.
Since 1984, the International Psycho-Oncology Society (IPOS) has been
committed to developing the science of psychosocial and behavioral oncology as
it relates to improving the care of cancer patients and their families, as
well as preventing cancer through healthy behaviors. IPOS is an individual
membership society serving psycho-oncology professionals throughout the world
and an umbrella organization serving national societies that represent over
5,000 research and clinical professionals in more than 50 countries.
Psycho-oncology stakeholders are multidisciplinary and include physicians,
psychologists, nurses, social workers, rehabilitation specialists,
epidemiologists, social scientists and educators.
Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, a market leader
in virology and active in other major therapeutic areas such as autoimmune
diseases, inflammation, metabolic disorders and diseases of the central
nervous system. Additional information is available on the Internet at
All trademarks used or mentioned in this release are protected by law.
Disclaimer: Cautionary statement regarding forward-looking statements
This document contains certain forward-looking statements. These
forward-looking statements may be identified by words such as 'believes',
'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks',
'estimates', 'future' or similar expressions or by discussion of, among other
things, strategy, goals, plans or intentions. Various factors may cause actual
results to differ materially in the future from those reflected in
forward-looking statements contained in this document, among others: (1)
pricing and product initiatives of competitors; (2) legislative and regulatory
developments and economic conditions; (3) delay or inability in obtaining
regulatory approvals or bringing products to market; (4) fluctuations in
currency exchange rates and general financial market conditions; (5)
uncertainties in the discovery, development or marketing of new products or
new uses of existing products, including without limitation negative results
of clinical trials or research projects, unexpected side-effects of pipeline
or marketed products; (6) increased government pricing pressures; (7)
interruptions in production; (8) loss of or inability to obtain adequate
protection for intellectual property rights; (9) litigation; (10) loss of key
executives or other employees; and (11) adverse publicity and news coverage.
The statement regarding earnings per share growth is not a profit forecast and
should not be interpreted to mean that Roche's earnings or earnings per share
for any current or future period will necessarily match or exceed the
historical published earnings or earnings per share of Roche.
1. Survey commissioned by Roche, conducted by Patient Research, 2007.
2. IARC. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence
Worldwide (2002 estimates). Accessed 2007 (http://www-dep.iarc.fr/).
For further information:
For further information: Media Relations Contacts: Lester B. Davis,
International Communication Manager, Tarceva, Lester.Davis@Roche.com; May
Baccari, Resolute Communications at May.Baccari@resolutecommunications.com,